Page 9 - Vaccine

Vaccines access could have prevented 50% Covid deaths globally: Research

Better access to vaccines could have prevented more than 50 per cent of Covid-19 deaths in 20 lower income countries, scientists contend in a new study

Pfizer and GSK to battle for share of new RSV vaccine market: Report

US drugmaker Pfizers and British pharma major GSK are likely to face significant competition in the respiratory syncytial virus (RSV) vaccine market, according to a report on Tuesday

CoWin data leak on Telegram channel alleged; Centre says portal 'safe'

Govt terms breach reports on Telegram 'mischievous'

Diseases know no borders, Covid underlined need for joint effort: Mandaviya

Mandaviya, in his address, highlighted the importance of collaborative research in mitigating and responding effectively to global health crises

Shortage of polio vaccines leads to cancellation of nation-wide vaccination

India administers two kinds of polio vaccines to children, first is the inactive polio vaccine (IPV) and the other is the bio-oral polio vaccine (bOPV) which contains live viruses to provide immunity

Lumpy skin disease returns; over 10,000 active cases reported till May 18

Uttarakhand, Maharashtra and Karnataka lead the way; 1.9 million vaccine doses administered in new cycle

US approves 1st vaccine for respiratory virus after decades of attempts

The US approved the first vaccine for RSV on Wednesday, shots to protect older adults against a respiratory virus that's most notorious for attacking babies but endangers their grandparents, too. The Food and Drug Administration decision makes GSK's shot, called Arexvy, the first of several potential vaccines in the pipeline for RSV to be licensed anywhere. The move sets the stage for adults 60 and older to get vaccinated this fall but first, the Centers for Disease Control and Prevention must decide if every senior really needs RSV protection or only those considered at high risk from the respiratory syncytial virus. CDC's advisers will debate that question in June. After decades of failure in the quest for an RSV vaccine, doctors are anxious to finally have something to offer especially after a virus surge that strained hospitals last fall. This is a great first step ... to protect older persons from serious RSV disease, said Dr. William Schaffner, medical director of the Natio

Vaccine market to reach valuation of Rs 252 bn by 2025: Jitendra Singh

Highlighting the country's strides in the pharma and biotechnology sector, Union Minister Jitendra Singh said the Indian vaccine market is expected to reach a valuation of Rs 252 billion by 2025

GSK to bring Herpes Zoster vaccine Shingrix at one-third of US price: MD

Shingrix is for the prevention of shingles or what is also known as herpes zoster and also post-herpetic neuralgia in people aged 50 and above, says GSK Pharmaceuticals MD Bhushan Akshikar

Paediatricians bat for Covid-19 vaccine for children as cases rise

Doctors say they are seeing an increase in children with Covid infection

Covid's endemic challenges

Public health policy must respond for the long term

Govt asks Maharashtra to buy vaccines to meet demand amid rising cases

Tamil Nadu, Kerala, Puducherry and Haryana are some of the states to have brought back fresh Covid-19 protocol, especially the mask mandate

Serum re-starts Covishield production, seeks to despatch 6 mn Covovax doses

Initiates talks with private hospitals for dispatching existing Covovax stock; Conducts in-vitro studies on human blood samples for neutralising antibody titres against XBB in India

Bihar CM Nitish urges Centre to provide fresh Covid-19 vaccine stocks

Bihar Chief Minister Nitish Kumar on Friday urged the Centre to provide fresh stocks of COVID vaccine vials so that administering of jabs, which is currently on hold, could be resumed. Talking to reporters here on the sidelines of a function, he also asserted that his government was "alert" in view of rising incidence of COVID cases in some parts of the country, though Bihar was not one of them. "Our testing rate is much higher than the national average, which is six lakh tests per one million people. We are conducting eight lakh tests. Bihar accounts for about one fourth of the total number of tests conducted across the country", claimed Kumar. He underscored that the current spike was noticed in those parts of the country which were the worst affected when the coronavirus had caused a global pandemic. "In Bihar cases are very few but we are alert, nonetheless. In places like hospitals wearing of masks is being reinforced. We were also carrying out vaccination till our supply drie

Few vaccination centres running amid steady surge in Covid-19 cases

230 of the 296 sites are private; people can now opt for mix-and-match doses of Corbevax and iNCOVACC

90% cattle vaccinated against lumpy skin disease in Punjab, says minister

Punjab's animal husbandry department is close to achieving 100 per cent vaccination of the 25 lakh cattle in the state against lumpy skin disease (LSD) and has inoculated more than 22 lakh of them. In an official statement issued on Saturday, Animal Husbandry Minister Laljit Singh Bhullar said the vaccination drive is nearing completion ahead of the April 30 deadline. "The vaccination drive for early protection of cattle from LSD was initiated on a war footing on February 15, 2023 with 773 dedicated veterinary teams of the animal husbandry department," he said. "We have completed 90 per cent vaccination till date, with more than 22,58,300 cattle already vaccinated," the minister said, adding the Chief Minister Bhagwant Mann-led government has set a target of vaccinating all the 25 lakh cattle in the state under this mega campaign. Principal Secretary, Animal Husbandry, Vikas Pratap said the department had set a daily target of administering 40,000 vaccine doses and has achieved it

Wockhardt plans to roll out two vaccines from UK plant in a year

Drug firm Wockhardt plans to roll out two vaccines within a year from its UK-based facility as part of a tie-up with Serum Institute of India, a top company official said. Last year, a Wockhardt unit tied up with a subsidiary of Serum Institute of India to set up a vaccine manufacturing facility in Wrexham, North Wales (UK). "Serum has identified two vaccines and we plan to manufacture these products within the next 12 months after exhibit batches and regulatory approval is received," Wockhardt Managing Director and Global CEO Murtaza Khorakiwala said in an analyst call. Elaborating on the tie-up, he noted that the company has already concluded an agreement with Serum and as a result of that Wockhardt has received 10 million pounds as a contribution for reserving the manufacturing facility for 150 million doses per year of vaccine for 15 years. "This is 150 million doses per year for about a 15-year agreement. And in addition to a contract manufacturing, there is a joint venture ..

IIT Delhi researcher develop next-gen vaccine using body's own immune cells

It was found that this antigen was more effective than free antigens in producing antibodies against the Covid-19 virus

Bharat Biotech rolls out India's first intra-nasal Covid vaccine iNCOVACC

Priced at Rs 800/dose for private players, Rs 325 for bulk procurement by govts

Production of vaccine against cervical cancer to be boosted: Poonawalla

A day after the first indigenously developed Human Papillomavirus vaccine against cervical cancer was launched, Serum Institute of India CEO Adar Poonawalla on Wednesday said the vaccine will be available in small quantity this year and its production will be boosted next year to take care of the needs of the nation. Speaking on the sidelines of an event after presenting the vaccine to Union Health Minister Mansukh Mandaviya, Poonawalla said the vaccine 'CERVAVAC' will be made available through the government programme this year. The vaccine for 9-14-year-old was launched on Tuesday in the presence of Union Home Minister Amit Shah, Poonawalla, and Director of Government and Regulatory Affairs at Serum Institute of India, Prakash K Singh. It will be available at a much lower price than the internationally branded vaccines available in the market, Singh had said earlier. The vaccine will be included in the National Immunisation Programme by mid-2023, government officials had said.